Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T A WALDMANN

Showing results (1-10 of 263) with videos related to

Pageof 27
Sort By:
Oncogene|May 29, 2007
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphomaT A Waldmann
Cancer Surveys|January 1, 1989
IL-2 receptor expression in the haematologic malignancies: a target for immunotherapyT A Waldmann
Trends in Pharmacological Sciences|May 1, 1993
The IL-2/IL-2 receptor system: a target for rational immune interventionT A Waldmann
Journal of the National Cancer Institute|June 21, 1989
Multichain interleukin-2 receptor: a target for immunotherapy in lymphomaT A Waldmann
Advances in Experimental Medicine and Biology|January 1, 1987
The interleukin-2 receptor on normal and malignant lymphocytesT A Waldmann
Clinical Immunology and Immunopathology|July 1, 1986
Immunodeficiency: immunoregulation and immunogeneticsT A Waldmann
Science (New York, N.Y.)|May 9, 1986
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytesT A Waldmann
Leukemia|August 1, 1993
1992 Stohlman Memorial Lecture: targeting the IL-2 receptorT A Waldmann
Important Advances in Oncology|January 1, 1994
Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphomaT A Waldmann
The Netherlands Journal of Medicine|October 1, 1991
Clinical immunology: past, present and future challenges and prospectsT A Waldmann
Pageof 27

Showing results (1-10 of 263) with videos related to

Sort By:
Pageof 27
Oncogene|May 29, 2007
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphomaT A Waldmann
Cancer Surveys|January 1, 1989
IL-2 receptor expression in the haematologic malignancies: a target for immunotherapyT A Waldmann
Trends in Pharmacological Sciences|May 1, 1993
The IL-2/IL-2 receptor system: a target for rational immune interventionT A Waldmann
Journal of the National Cancer Institute|June 21, 1989
Multichain interleukin-2 receptor: a target for immunotherapy in lymphomaT A Waldmann
Advances in Experimental Medicine and Biology|January 1, 1987
The interleukin-2 receptor on normal and malignant lymphocytesT A Waldmann
Clinical Immunology and Immunopathology|July 1, 1986
Immunodeficiency: immunoregulation and immunogeneticsT A Waldmann
Science (New York, N.Y.)|May 9, 1986
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytesT A Waldmann
Leukemia|August 1, 1993
1992 Stohlman Memorial Lecture: targeting the IL-2 receptorT A Waldmann
Important Advances in Oncology|January 1, 1994
Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphomaT A Waldmann
The Netherlands Journal of Medicine|October 1, 1991
Clinical immunology: past, present and future challenges and prospectsT A Waldmann
Pageof 27